Vancouver
Originally published online as doi:10.1189/jlb.0205102 on June 16, 2005

Published online before print June 16, 2005
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
jlb.0205102v1
78/3/716    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, K.
Right arrow Articles by Braley-Mullen, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, K.
Right arrow Articles by Braley-Mullen, H.
(Journal of Leukocyte Biology. 2005;78:716-724.)
© 2005 by Society for Leukocyte Biology

Chemokine expression during development of fibrosis versus resolution in a murine model of granulomatous experimental autoimmune thyroiditis

Kemin Chen*,1, Yongzhong Wei*, Adam Alter*, Gordon C. Sharp* and Helen Braley-Mullen*,{dagger},{ddagger}

* Departments of Internal Medicine and
{dagger} Molecular Microbiology & Immunology, University of Missouri School of Medicine, and
{ddagger} VA Research Service, Columbia

1Correspondence: Division of Immunology & Rheumatology, Department of Medicine, University of Missouri, M306 Medical Sciences, One Hospital Dr., Columbia, MO 65212. E-mail: Chenk{at}health.missouri.edu

Severe granulomatous experimental autoimmune thyroiditis (G-EAT) in DBA/1 or CBA/J wild type (WT) mice at day 19 progresses to fibrosis by day 35, but severe G-EAT in DBA/1 interferon (IFN)-{gamma}–/– mice or less-severe G-EAT at day 19 in WT mice resolves by day 35. To study the role of chemokines in autoimmune diseases and fibrosis, profiles of chemokines and chemokine receptors were analyzed in DBA/1 WT versus IFN-{gamma}–/– and CBA/J thyroids, which have distinct outcomes of autoimmune inflammation. Gene expression of CXC chemokine ligand 1 (CXCL1) and CXC chemokine receptor 2 (CXCR2) paralleled neutrophil infiltration and thyrocyte destruction in DBA/1 WT or CBA/J thyroids, and gene expression of CC chemokine ligand 11 (CCL11), CCL8, and CC chemokine receptor 3 paralleled eosinophil infiltration in IFN-{gamma}–/– thyroids. Gene and protein expression of CXCL10, CXCL9, and CXCR3 was significantly lower in IFN-{gamma}–/– compared with DBA/1 WT thyroids. Moreover, immunostaining showed that CXCL10 was expressed by thyrocytes and inflammatory cells, and strong expression of CXCL10 by thyrocytes was as early as day 7. High expression of CCL2 was only observed in severely destroyed DBA/1 WT or CBA/J thyroids, which would develop fibrosis. Thus, the differential expression of chemokines may direct distinct cellular populations in DBA/1 WT versus IFN-{gamma}–/– thyroids. Up-regulation of CXCL10 by thyrocytes suggests its role in regulating the recruitment of specific subsets of activated lymphocytes to the thyroid during autoimmune inflammation. The early expression of CXCL1, CXCL10, and CCL2 may suggest their involvement in the initiation and perpetuation of disease in severe G-EAT thyroids, which progress to fibrosis.

Key Words: chemokine receptors • autoimmune inflammation • collagen • autoimmune diseases • resolution




This article has been cited by other articles:


Home page
 EndocrinologyHome page
E. Borgogni, E. Sarchielli, M. Sottili, V. Santarlasci, L. Cosmi, S. Gelmini, A. Lombardi, G. Cantini, G. Perigli, M. Luconi, et al.
Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells
Endocrinology, July 1, 2008; 149(7): 3626 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yu, G. C. Sharp, and H. Braley-Mullen
Thyrocytes Responding to IFN-{gamma} Are Essential for Development of Lymphocytic Spontaneous Autoimmune Thyroiditis and Inhibition of Thyrocyte Hyperplasia
J. Immunol., January 15, 2006; 176(2): 1259 - 1265.
[Abstract] [Full Text] [PDF]